NCT05177068 2025-10-02
Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer
Henan Cancer Hospital
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT06329973 2025-07-17
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
Henan Cancer Hospital
Phase 1/2 Recruiting
NCT05495152 2024-10-02
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
Phase 3 Recruiting
NCT06227325 2024-01-26
Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
Henan Cancer Hospital
Phase 2 Unknown
NCT04055792 2023-06-28
Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Henan Cancer Hospital
Phase 2 Completed
NCT05207735 2022-01-26
SCRCA
Henan Cancer Hospital
Phase 2 Unknown